Verastem, Inc. (VSTM)
8.73
+0.03
(+0.34%)
USD |
NASDAQ |
Nov 10, 16:00
8.88
+0.15
(+1.72%)
After-Hours: 20:00
Verastem Cash from Operations (Annual) : -137.51M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -137.51M |
| December 31, 2024 | -104.77M |
| December 31, 2023 | -86.46M |
| December 31, 2022 | -63.67M |
| December 31, 2021 | -53.50M |
| December 31, 2020 | -35.27M |
| December 31, 2019 | -138.96M |
| December 31, 2018 | -74.52M |
| Date | Value |
|---|---|
| December 31, 2017 | -57.31M |
| December 31, 2016 | -29.48M |
| December 31, 2015 | -45.56M |
| December 31, 2014 | -36.90M |
| December 31, 2013 | -26.30M |
| December 31, 2012 | -22.60M |
| December 31, 2011 | -10.13M |
| December 31, 2010 | -0.33M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Cytokinetics, Inc. | -510.01M |
| Inovio Pharmaceuticals, Inc. | -88.63M |
| Rigel Pharmaceuticals, Inc. | 75.66M |
| United Therapeutics Corp. | 1.561B |
| SELLAS Life Sciences Group, Inc. | -28.39M |